Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

1.690 -0.050 (-2.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,529,962
Open 1.750
Bid (Size) 1.690 (8)
Ask (Size) 1.720 (10)
Prev. Close 1.740
Today's Range 1.660 - 1.750
52wk Range 1.639 - 12.51
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lead Plaintiff Deadline is July 14, 2025 for Investors of Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox
Via TheNewswire.com
Topics Lawsuit
Lead Plaintiff Deadline is July 14, 2025 for Investors of Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit

Performance

YTD
-78.3%
-78.3%
1 Month
-3.4%
-3.4%
3 Month
-52.5%
-52.5%
6 Month
-77.1%
-77.1%
1 Year
-78.9%
-78.9%

More News

Read More
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
Via The Motley Fool
IOVA DEADLINE NOTICE: Iovance Biotherapeutics Investors that Suffered Losses are Notified of the July 14 Class Action Deadline -- Contact BFA Law
Via ACCESS Newswire
Iovance Biotherapeutics, Inc. Class Action: Levi & Korsinsky Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 14, 2025 - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
Iovance Biotherapeutics, Inc. Class Action: Levi & Korsinsky Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 14, 2025 - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure - Hagens Berman
Via ACCESS Newswire
IOVA SECURITIES NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud - Contact BFA Law by July 14 if You Suffered Losses
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Via ACCESS Newswire
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 14, 2025 - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 14, 2025 - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Via ACCESS Newswire
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 14, 2025 - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 14, 2025 - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
BFA Law Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors that the Company was Sued for Fraud - Contact the Firm by July 14 if You Lost Money
Via ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Via ACCESS Newswire
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
From The Rosen Law Firm PA
Via GlobeNewswire
Deadline Approaching for Investors of Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox Before July 14, 2025
Via NewMediaWire
Topics Lawsuit
Deadline Approaching for Investors of Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox Before July 14, 2025
Via TheNewswire.com
Topics Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 1.690
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 06/27/25 04:00 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 515.88M
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 516M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.